Cited 0 times in Scipus Cited Count

Gastrointestinal/genitourinary perforation and fistula formation with or without bevacizumab in patients with previously irradiated recurrent cervical cancer: a Korean multicenter retrospective study of the Gynecologic Oncology Research Investigators Collaboration (GORILLA) group (GORILLA-1001)

DC Field Value Language
dc.contributor.authorHwang, WY-
dc.contributor.authorChang, SJ-
dc.contributor.authorKim, HS-
dc.contributor.authorKim, NK-
dc.contributor.authorKim, TH-
dc.contributor.authorKim, Y-
dc.contributor.authorKong, TW-
dc.contributor.authorLee, EJ-
dc.contributor.authorPark, SJ-
dc.contributor.authorShim, SH-
dc.contributor.authorSon, JH-
dc.contributor.authorSuh, DH-
dc.contributor.authorYang, EJ-
dc.date.accessioned2023-02-13T06:23:14Z-
dc.date.available2023-02-13T06:23:14Z-
dc.date.issued2022-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/24522-
dc.description.abstractBACKGROUND: This study aims to evaluate the incidence of and identify risk factors for gastrointestinal (GI) and genitourinary (GU) fistula or perforation formation with or without bevacizumab in patients with recurrent cervical cancer who underwent pelvic radiation therapy (RT). METHODS: Medical records of patients with recurrent cervical cancer who previously underwent pelvic RT between 2007 and 2020 were retrospectively reviewed. Clinicopathological factors were compared between groups that are stratified according to: 1) fistula/perforation (+) versus (-); and 2) bevacizumab plus conventional chemotherapy (BC) versus chemotherapy alone (C). Univariate and multivariate regression analyses were performed to identify risk factors for fistula/perforation. Overall survival (OS) was compared between the different groups. RESULTS: Of 219 participants, fistula/perforation of any grade occurred in 36 patients (16.4%); 27 fistulas and 9 perforations. Bevacizumab was more frequently used in Bevacizumab was more frequently used ( +) group than fistula/perforation (-) group (p = 0.015). Multivariate analysis showed that bevacizumab administration was the only independent risk factor for fistula or perforation (HR, 3.27; 95% CI, 1.18-9.10; P = 0.023). F/P was observed more frequently in women receiving BC (n = 144) than those receiving C (n = 75) (20.8% vs. 8.0%; P = 0.019). During median follow-up of 33.7 months (1.2-185.6 months), no significant OS difference was observed between fistula/perforation ( +) vs. (-) (hazards ratio [HR], 1.78; median 84.2 months [95% CI, 59.3-109.0] vs. 129.5 months [95% CI, 114.1-144.9]; P = 0.065) or BC vs. C (HR, 1.03; median 119.8 months [95% CI, 97.3-142.3] vs. 115.7 months [95% CI, 96.0-135.4]; P = 0.928). CONCLUSIONS: This study suggests that incorporation of bevacizumab in chemotherapy regimens for treating recurrent cervical cancer in patients who underwent pelvic RT incurs considerable risk for GI/GU fistula or perforation. There were no other independent risk factors for developing GI/GU fistula or perforation in this study population.-
dc.language.isoen-
dc.subject.MESHAnimals-
dc.subject.MESHBevacizumab-
dc.subject.MESHFemale-
dc.subject.MESHFistula-
dc.subject.MESHGorilla gorilla-
dc.subject.MESHHumans-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHUterine Cervical Neoplasms-
dc.titleGastrointestinal/genitourinary perforation and fistula formation with or without bevacizumab in patients with previously irradiated recurrent cervical cancer: a Korean multicenter retrospective study of the Gynecologic Oncology Research Investigators Collaboration (GORILLA) group (GORILLA-1001)-
dc.typeArticle-
dc.identifier.pmid35655188-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161567-
dc.subject.keywordBevacizumab-
dc.subject.keywordCervical cancer-
dc.subject.keywordChemotherapy-
dc.subject.keywordComplication-
dc.subject.keywordRadiation-
dc.contributor.affiliatedAuthorChang, SJ-
dc.contributor.affiliatedAuthorKong, TW-
dc.contributor.affiliatedAuthorSon, JH-
dc.type.localJournal Papers-
dc.identifier.doi10.1186/s12885-022-09695-x-
dc.citation.titleBMC cancer-
dc.citation.volume22-
dc.citation.number1-
dc.citation.date2022-
dc.citation.startPage603-
dc.citation.endPage603-
dc.identifier.bibliographicCitationBMC cancer, 22(1). : 603-603, 2022-
dc.identifier.eissn1471-2407-
dc.relation.journalidJ014712407-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Obstetrics & Gynecology
Files in This Item:
35655188.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse